Discover the potential of INF904, a groundbreaking oral therapy targeting C5aR for hidradenitis suppurativa and chronic spontaneous urticaria, promising new treatment options.
Camilla Chong, MD
Advertisement
Camilla Chong, MD, is chief medical officer at InflaRx.
Articles by Camilla Chong, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
How Clinicians are Navigating JAK Inhibitors and Patient Expectations in Alopecia Areata
5
